GLP-1 Therapies Research,
what lands in your inbox each week:
- 📚7 fresh studies
- 📝plain-language summaries
- ✅direct links to original studies
- 🏅top journal indicators
- 📅weekly delivery
- 🧘♂️always free
some of our latest newsletters:
(select one to read it below)
New obesity drug survodutide cut weight by 13% vs 5.4% for placebo in 725 patients
GLP-1 drugs like Ozempic have transformed obesity treatment, but the field keeps evolving. This week brought major updates on everything from new drug candidates to what happens when people stop taking these medications.
🎯 New obesity drug beats placebo by wide margin in phase 3 trial
- Survodutide (a dual hormone receptor drug) reduced body weight by 12.2-13.0% compared to 5.4% for placebo in 725 adults with obesity over 76 weeks
- 72.6% and 71.9% of patients on the two survodutide doses lost at least 5% of body weight, compared to 46.3% on placebo
- Most common side effects were gastrointestinal (mild to moderate nausea, vomiting) in 81-90% of survodutide users vs 48% of placebo users
Why it matters: This represents another major advance in obesity pharmacotherapy, with weight loss approaching what's typically seen with bariatric surgery, though the high rate of GI side effects mirrors challenges seen with existing GLP-1 drugs.
Key Findings
💊 First daily oral GLP-1 pill shows promise in obesity trial
- Elecoglipron (a small molecule taken once daily without food restrictions) produced 2.6-10.5% weight loss compared to 0.6% for placebo in 310 participants over 26 weeks
- 40-89% of patients achieved at least 5% weight loss depending on dose, compared to 16% on placebo
- Side effects were typical GLP-1 class (nausea, constipation, diarrhea) but the convenience factor could be game-changing
⚖️ Most people regain weight rapidly after stopping GLP-1 drugs
- Up to 65% of users discontinue GLP-1 medications within a year of starting them
- Two-thirds of lost weight is typically regained within a year of stopping treatment
- Weight regain reflects biological mechanisms that promote returning to previous weight once appetite suppression is removed
🧠 GLP-1 drug's antidepressant effects work through gut bacteria, not brain receptors
- Liraglutide reduced depression in mice even when GLP-1 brain receptors were blocked or missing entirely
- The drug increased Lactobacillus delbrueckii bacteria, which boosted brain chemicals called endocannabinoids
- Transplanting gut bacteria from liraglutide-treated mice into other mice replicated the antidepressant effects
🏥 GLP-1 users had fewer overdoses and hospitalizations in addiction study
- Among 107,217 patients with both opioid and alcohol use disorders, those prescribed GLP-1 drugs had 52% lower risk of overdose (hazard ratio 0.48)
- GLP-1 users also had reduced rates of substance use disorder-related hospitalizations across most patient subgroups
- Effects were most pronounced in patients also receiving standard addiction medications
💪 Experimental drug preserved muscle mass during GLP-1 weight loss
- Apitegromab (which blocks a muscle-wasting protein called myostatin) prevented 1.9 kg of lean muscle loss compared to placebo in 102 people taking tirzepatide
- Both groups lost similar total weight, but the apitegromab group retained 55% more muscle mass
- This addresses a key concern that rapid weight loss from GLP-1 drugs includes too much muscle loss
🔬 Ketone supplements prevented muscle loss from semaglutide in mice
- Mice given semaglutide alone lost muscle mass and strength, but those also receiving ketone esters maintained both
- Ketone supplementation prevented changes in genes related to muscle breakdown and mitochondrial function
- Fat loss was preserved in both groups, suggesting ketones specifically protected muscle tissue
Implications
The GLP-1 revolution continues expanding with new drugs, delivery methods, and combination approaches addressing key limitations like muscle loss and discontinuation. These findings suggest the field is maturing beyond simple weight loss toward more sophisticated, personalized obesity treatments.
Science is the only real news.
The rest is just drama 📰
And nowadays, we see that drama everywhere.
Drama sells ads, ads sell products, and my attention sells to the highest bidder.
Drama media is junk food for the mind.
A quick rush, hard to avoid, but little nutritional value.
The brain wants broccoli 🧠🥦
And look, it's not that science never makes the news.
But think about when it does—does the news really understand the science it reports on?
Like it or not, AI exists now.
And it happens to be a huge science nerd… 🔭🤖
…with a superpower…
...unlike an average science nerd, AI can explain it simply.
I built OpenScience to make the constant stream of new studies accessible to anyone.
To free science from academic jargon and tiny-fonted PDFs.
OpenScience is a weekly newsletter of 7 compelling studies from the past week in the topic of your choice.
Made simple, digestible, and delightful by AI.
Interested in CRISPR?
The latest Long Covid research?
Psychedelic medicine?
Follow the actual science, as it comes out.
Every study is linked to the original PubMed so you can verify the AI's summary yourself.
Pick a topic, get the weekly email, and give your mind the broccoli it deserves 🥦
The real-time unfolding of science is too interesting not to follow.